Human Genome Project; Co-Founder of Illumigen Biosciences ($340M exit) and Kineta; Established and grew five Kineta drug programs; 1st Kv1.3 inhibitor in Clinic; Secured >$57M R&D funding grants

25+ years in commercial operations in the pharmaceutical industry; marketing, payer strategy, pricing, national accounts, sales leadership and business development at GSK and Schering-Plough.

15+ years of legal experience in both in-house and outside counsel roles; general corporate matters, financing, licensing, intellectual property, M&A and other legal and strategic matters

43 years of banking and fund raising experience. Corporate Development at Kineta; Founding CEO Seattle Savings Bank; Past president Seattle Kiwanis, Chamber of Commerce, Seafair Commodores

15+ years of experience in immunology/infectious disease research and translational drug development; founding scientist at Kineta; leads strategy and development for nonclinical, clinical, and CMC

Craig Philips serves as the President of Kineta. He has over 30 years of pharmaceutical industry experience at both Fortune 500 pharmaceutical and smaller biotech companies. Mr. Philips has been with Kineta since 2013 in different executive management roles.

Chanya Swartz serves as Kineta’s Sr. Director of Finance and Corporate Controller, leading the finance and accounting functions for Kineta and its subsidiaries. She brings with her over twenty years of international experience in both public and private companies.